ATRC
AtriCure, Inc. · NASDAQ
- Sector Health Technology
- Industry Medical Specialties
- Website atricure.com
- Employees(FY) 1050
- ISIN US04963C2098
Performance
+5.18%
1W
+0.17%
1M
-29.28%
3M
-44.81%
6M
-35.16%
YTD
-52.41%
1Y
Profile
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Investment Analysis Report: ATRC
Overview
In this investment analysis report, we will delve into the financial statements of ATRC, a company operating in the Health Technology sector within the Medical Specialties industry. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operating cas...
Technical Analysis of ATRC 2024-05-10
Overview:
In analyzing the provided ATRC TA data for the last 5 days, we will delve into the technical indicators across trend, momentum, volatility, and volume to forecast the possible stock price movement in the upcoming days. By examining key metrics such as moving averages, MACD, RSI, Bollinger Bands, and OBV, we aim to provide a comprehensi...
Recent News & Updates
- 2024-05-15 08:00
- 2024-05-14 20:00
- 2024-05-04 08:52
- 2024-05-03 07:33
- 2024-05-03 07:18
- 2024-05-02 15:18
AtriCure, Inc. (NASDAQ:ATRC) Q1 2024 Earnings Call Transcript(Insider Monkey)
- 2024-05-02 03:49
- 2024-05-02 03:18
- 2024-05-01 20:36
- 2024-05-01 20:00
- 2024-05-01 17:55
- 2024-05-01 17:30
- 2024-05-01 16:34
AtriCure: Q1 Earnings Snapshot(Associated Press Finance)
- 2024-05-01 16:01
AtriCure Reports First Quarter 2024 Financial Results(Business Wire)
- 2024-05-01 08:57
- 2024-05-01 08:00
- 2024-05-01 05:30
- 2024-05-01 04:01
AtriCure Reports First Quarter 2024 Financial Results(Businesswire)
- 2024-04-30 08:00
- 2024-04-29 20:00
- 2024-04-23 07:07
- 2024-04-19 09:45
- 2024-04-18 21:45
- 2024-04-18 08:00
- 2024-04-17 20:00
- 2024-04-10 08:00
AtriCure to Announce First Quarter 2024 Financial Results(Business Wire)
- 2024-04-09 20:00
- 2024-03-26 08:00
- 2024-03-25 20:00
- 2024-03-22 06:40
AtriCure (ATRC) Declined due to Concerns Over Anti-Obesity Drug(Insider Monkey)
Page 1 of 6
previousnext